Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease in Conjunction With Long-term Outcome
Phase of Trial: Phase IV
Latest Information Update: 19 Jul 2018
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms RUN-CD Study
- 12 Jul 2018 Planned End Date changed from 30 May 2022 to 31 Mar 2023.
- 12 Jul 2018 Planned primary completion date changed from 31 Mar 2022 to 31 Mar 2023.
- 22 May 2018 Planned number of patients changed from 600 to 900.